TCZ is also considered to be effective for the treatment of chimeric antigen receptor T cell therapy (CAR T-cells) related CRS.[12] Considering the key role of IL-6 blocking by TCZ in the treatment of CAR T-cells CRS and the role of IL-6 in COVID-19 CRS, TCZ was rapidly considered as a potential benefit treatment for COVID-19 CRS. This evidence concerns the gene IL6 and congenital rubella syndrome.